Atlantia Food Clinical Trials returns as Innovation Partner to the 4th Microbiome Movement – Drug Development Europe 2020 in London
Atlantia Food Clinical Trials returns as Innovation Partner to the 4th Microbiome Movement – Drug Development Europe 2020, one of the main industry meeting dedicated to evidence-based microbiome research & development in disease treatment.
This edition will be hosted on 4-6th February at the Tower Hotel in London. This event combines more than 12 hours of workshops with conferences from more than 40 expert speakers from both industry and academia. This edition’s main topics are:
- Functionality, mechanisms & preclinical development of microbiome-based therapeutics.
- Clinical translation, manufacturing & commercialization of microbiome-based therapeutics.
Across three days of case-studies, discussion and debates, the organisers have defined the following as the ten key questions to be explored and answered around the below mention topics:
- What are the targets, platforms, and challenges for novel live biotherapeutics?
- How can you demonstrate a causative clinical benefit for microbiome-based therapeutics?
- How are organisations scaling and manufacturing microbiome-based therapeutics?
- What are the limitations when translating animal studies to humans?
- What is the role of the microbiome in cancer therapy response?
- How can strategic collaborations drive the future of microbiome-based applications in healthcare?
- How can start-ups raise capital to accelerate microbiome-focused drug platforms?
- How is the human microbiome blurring the lines between food and pharma?
- How can researchers utilise synthetic biology to engineer bacteria as living therapeutics?
- Will phage therapeutics hold the key to modulating the microbiome?
Our Medical Director, Professor Ted Dinan, will be speaking about Food, Mood and the Gut Microbiota on Wednesday 5 February. He will be sharing evidence to support the impact gut microbes have on central neurochemistry and behaviour, especially in stress related disorders such as depression. He will be also presenting recent studies indicating patients with depression have gut microbiome dysbiosis.
Do you want to meet our clinical team at the 4th Microbiome Movement – Drug Development Europe 2020?
Schedule a meeting with us at the show or in London!
Check the highlights from the 2019 edition: